A Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152

A Randomized, Open-labeled, Oral Dose, Crossover Design Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152 in Healthy Male Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02502721

Enrollment

Registered

2015-07-20

Start date

2015-06-30

Completion date

2015-08-31

Last updated

2015-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Male

Brief summary

A randomized, open-labeled, oral dose, crossover design clinical trial to evaluate pharmacokinetics and safety between DWC20151 and DWC20152 in healthy male subjects.

Detailed description

This study is to evaluate pharmacokinetics and safety between DWC20151 and DWC20152 in healthy male subjects. Study design is randomized, open-labeled, oral dose, crossover design. This study will conducted with 2 separated part (Part A, Part B).

Interventions

DRUGDWC20151

DRUGDWC20152

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male subjects (18\ 55 years)

Exclusion criteria

* Who has allergy to investigational product

Design outcomes

Primary

Measure	Time frame
Peak Plasma Concentration (Cmax)	0~72hr
Area under the plasma concentration versus time curve (AUC)	0~72h

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026